Neopharmed Gentili acquires the European ORLADEYO® Business from BioCryst Pharmaceuticals
Italian pharmaceutical company strengthens position in the field of rare diseases
Neopharmed Gentili (“Neopharmed”), an Italian pharmaceutical company active in the marketing of high-value therapeutic solutions, controlled by the Del Bono Family and two leading international private equity firms, Ardian and Renaissance Partners, announces the acquisition of the European ORLADEYO® (berotralstat) business from BioCryst Pharmaceuticals. ORLADEYO is the first oral, once-daily plasma kallikrein inhibitor indicated for the treatment of hereditary angioedema (HAE).
This transaction is consistent with Neopharmed’s strategy of replicating its success in Italy at the European level, while strengthening its portfolio by entering the high value and fast-growing rare disease space. Neopharmed is acquiring BioCryst’s European organization, which will enable commercial continuity for ORLADEYO available to patients in Europe through the resources, capabilities and know-how BioCryst built in the HAE field. This transaction puts Neopharmed in a strong position to create value beyond ORLADEYO and drive sustainable growth well into the next decade through pipeline expansion in specialty pharmaceuticals and rare disease therapies.
Neopharmed is acquiring a rare disease business that is set to grow 30%+ YoY in 2025, generating c. €50 Million in sales with significant long-term growth runway, and an established and scalable specialty platform to support additional portfolio expansion.
ORLADEYO® and the European team responsible for its success represent a first step in Neopharmed becoming the partner of choice and consolidator of rare disease assets in Europe.
“This transaction marks the beginning of a new path for Neopharmed Gentili, projecting the company into the international stage and rare disease field, leveraging its deep Italian roots and welcoming a successful and experienced European team.” said Alessandro Del Bono, President and CEO of Neopharmed Gentili. “This acquisition confirms and further strengthens our long-term growth trajectory, consolidating our positioning as a leading European specialty pharmaceutical company. I would like to thank BioCryst’s CEO Jon Stonehouse and his team for the collaborative spirit that underpinned our discussions. I would also like to congratulate the Neopharmed team for this transaction which marks a key step in our long-term strategic journey and to thank them for their hard work and commitment to this process.”
“This transaction is consistent with our strategy of making ORLADEYO available to patients in Europe through the team we built, and puts us in an even stronger position to create value beyond ORLADEYO and sustainable growth well into the next decade through our pipeline and potential external opportunities,” said Jon Stonehouse, President and CEO of BioCryst. “We believe Neopharmed Gentili will be able to leverage ORLADEYO and this outstanding team to launch a capital efficient strategy that makes a ton of sense and could develop into a thriving European Rare disease business that could become the partner of choice for U.S. rare disease companies, including BioCryst when we advance additional products to the market.”
Other news from the department business & finance
